Novel Targeted Antibody-Drug Conjugates in Non-Hodgkin Lymphoma
Pharma & biotech2018-06-18
1 Views
Antibody-drug conjugates represent a targeted class of agents with an improved therapeutic index over traditional chemotherapy in the treatment of non-Hodgkin lymphoma.
Source: OncLive
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
FDA Approves Aurinia Pharmaceuticals' (Nasdaq: AUPH / TSX: AUP) LUPKYNIS (voclosporin) for Adult Patients with Active Lupus Nephritis
